Rivastigmine Tartrate Capsule
Product Images NDC 65862-649

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Rivastigmine Tartrate (NDC 65862-649). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Rivastigmine Fig1)

The text describes a figure showing the time-course of the change from a baseline ADAS-cog score for patients completing 26 weeks of treatment in a study. The figure shows the mean change from baseline and indicates clinical improvement, clinical decline, and the use of 1-4mg of an unnamed medication and a placebo. The figure is assessed at various weeks during treatment up to 26 weeks.*

FDA Label Image

Package Label-principal Display Panel (1.5 mg Blister Carton (10 x 10 Unit-dose))

This is a description of Rivastigmine Tartrate Capsules, USP. The capsules are only available with a prescription and come in a pack of 100 units, which are each a 1.5 mg dose of rivastigmine tartrate. The manufacturer of the capsules is Aurobindo. There are also some unreadable characters and text that seem to be unrelated to the description.*

FDA Label Image

Package Label-principal Display Panel (3 mg (60 Capsules Bottle))

This is a description of a drug called Rivastigmine Tartrate, which comes in the form of capsules. The NDC number for the drug is available. It's a prescription drug, and each capsule contains 3 mg of Rivastigmine tartrate. Dosage information can be found in the package insert. The drug should be stored at room temperature and kept in a tight container. The drug is distributed by Aurobindo Pharma USA, Inc. and made in India.*

FDA Label Image

Package Label-principal Display Panel (3 mg Blister Carton (10 x 10 Unit-dose))

This is a description of a medication called Rivastigmine Tartrate Capsules, USP. It comes in a package of 100 capsules with each capsule containing 3 mg of rivastigmine tartrate. This medication is available by prescription only and is used for treating a condition called dementia. Other than this, there is a section of illegible text at the bottom which cannot be interpreted.*

FDA Label Image

Package Label-principal Display Panel (4.5 mg (60 Capsules Bottle))

This is a prescription drug identified by the National Drug Code 65862-650-60. It is a 60 capsule pack of Rivastigmine Tartrate USP Capsules used to treat dementia. Each capsule is 4.5 mg in equivalent weight. Dosage information is available on the package insert. It should be stored between 20° to 25°C (68° to 77°F) and in a tight container. This drug is distributed by Aurobindo Pharma USA, Inc., located in East Windsor, NJ, 08520 and is manufactured in India.*

FDA Label Image

Package Label-principal Display Panel (4.5 mg Blister Carton (10 x 10 Unit-dose))

This is a label for Rivastigmine Tartrate Capsules, USP. It contains important information such as the quantity of capsules (100), dose (4.5 mg per capsule), and manufacturer (Aurobindo). It also includes a prescription warning and a National Drug Code (NDC) number for identification.*

FDA Label Image

Package Label-principal Display Panel (6 mg (60 Capsules Bottle))

FDA Label Image

Package Label-principal Display Panel (6 mg Blister Carton (10 x 10 Unit-dose))

Rivastigmine Tartrate Capsules, USP is a prescription drug that comes in the form of unit-dose capsules. Each capsule contains 6 mg of rivastigmine tartrate, a medication used to improve memory and thinking in patients with Alzheimer's disease. The NDC number for this product is 65862-651-78 and it is manufactured by Aurobindo.*

FDA Label Image

Figure 2 (Rivastigmine Fig2)

FDA Label Image

Figure 3 (Rivastigmine Fig3)

The text provides a chart showing the frequency distribution of CIBIC-Plus scores at week 26 in Study 1. The chart includes the percentage of patients and the CIBIC-Plus rating based on the score. The chart compares the scores of patients who took either a placebo or different doses of medication (1 to 4mg, 6 to 12mg). Therefore, it is a useful graphical representation of the study's outcomes.*

FDA Label Image

Figure 4 (Rivastigmine Fig4)

The figure shows the change in ADAS-cog score over 26 weeks of treatment for patients. The ADAS-cog score is used to assess cognitive function in patients with Alzheimer's disease. The graph depicts the change from baseline in ADAS-cog score over time for patients either receiving treatment or a placebo. The x-axis represents the weeks during treatment, while the y-axis represents the change in ADAS-cog score. There is no further text available for description.*

FDA Label Image

Figure 5 (Rivastigmine Fig5)

The text describes a figure showing the percentage of patients who completed a 26-week double-blind treatment and their ADAS-cog scores. The study includes different treatment groups with different dosages (placebo, 1-4 mg, and 6-12 mg). The figure shows a cumulative percentage of patients completing the treatment with specified changes in their ADAS-cog scores. The percentages of randomized patients who completed the study for each treatment group are also provided.*

FDA Label Image

Figure 6 (Rivastigmine Fig6)

Frequency distribution of CIBIC-Plus scores at week 26 in Study 2 is shown in Figure 6. This chart shows the percentage of patients falling under the category of markedly improved, moderately improved, minimally improved, unchanged, minimally worse, moderately worse, and markedly worse. The study was conducted with a placebo and two dosage levels of a medication. The dosage levels were 1 to 6 mg and 6 to 12 mg. The text appears to be a part of a clinical trial report.*

FDA Label Image

Figure 7 (Rivastigmine Fig7)

Figure 7 shows the time course of change from baseline in ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale) score for patients who completed 24 weeks of treatment. The graph includes mean (+/- SEM) change from baseline in ADAS-cog rating for clinical improvement, rivastigmine tartrate treatment, clinical decline, and placebo at weeks 8, 16, and 24 during treatment.*

FDA Label Image

Figure 8 (Rivastigmine Fig8)

The figure shows the distribution of ADCS-CGIC scores for patients who completed 24 weeks of treatment in Study 4. The graph displays the percentage of patients who received Rivastigmine Tartrate or placebo, with different levels of improvement ranging from markedly improved to markedly worse. The percentage of patients is represented on the Y-axis, and the various levels of improvement are represented on the X-axis.*

FDA Label Image

Package Label-principal Display Panel – 1.5 mg (60 Capsule Bottle) (Rivastigmine Fig9)

The text describes a medication called Rivastigmine Tartrate USP, which is contained in capsules manufactured by Aurobindo. Each capsule contains 1.5 mg of the medication, with 60 capsules in each container. The usual dosage instructions can be found in the package insert. The medication should be stored at room temperature and kept in a tightly closed container. The medication is for prescription use only, and distributed by Aurobindo Pharma USA. The medication is manufactured in India.*

FDA Label Image

Chemical Structure (Rivastigmine Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.